Advertisement

Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis

  • Clàudia Coll-Martinez
    Affiliations
    Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain

    Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain

    Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain
    Search for articles by this author
  • Ester Quintana
    Affiliations
    Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain
    Search for articles by this author
  • Maria Buxó
    Affiliations
    Girona Biomedical Research Institute (IDIBGI), Salt, Spain
    Search for articles by this author
  • Judit Salavedra-Pont
    Affiliations
    Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain

    Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain
    Search for articles by this author
  • Laia Gasull-Vicens
    Affiliations
    Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain
    Search for articles by this author
  • Ana Quiroga-Varela
    Affiliations
    Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain

    Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain
    Search for articles by this author
  • Lucienne Costa-Frossard
    Affiliations
    Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain

    Neurology Department, Ramon y Cajal University Hospital, Madrid, Spain

    Universidad de Alcalá, Madrid, Spain

    Multiple Sclerosis Group, Instituto Ramón y Cajal de investigación Sanitaria (IRYCIS), Madrid, Spain
    Search for articles by this author
  • Luisa María Villar
    Affiliations
    Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain

    Multiple Sclerosis Group, Instituto Ramón y Cajal de investigación Sanitaria (IRYCIS), Madrid, Spain

    Immunology Department, Ramon y Cajal University Hospital, Madrid, Spain
    Search for articles by this author
  • Eva Fernández-Díaz
    Affiliations
    Neurology Department, Albacete University Hospital Albacete, Spain
    Search for articles by this author
  • Julia Gracia
    Affiliations
    Neurology Department, Albacete University Hospital Albacete, Spain
    Search for articles by this author
  • Yolanda Aladro
    Affiliations
    Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain

    Neurology Department, Getafe University Hospital, Madrid, Spain

    Universidad Europea de Madrid, Madrid, Spain
    Search for articles by this author
  • Alejandro Méndez-Burgos
    Affiliations
    Neurology Department, Getafe University Hospital, Madrid, Spain

    Universidad Europea de Madrid, Madrid, Spain
    Search for articles by this author
  • Marta Cerezo
    Affiliations
    Neurology Department, Getafe University Hospital, Madrid, Spain

    Universidad Complutense de Madrid, Madrid, Spain
    Search for articles by this author
  • Lluís Ramió-Torrentà
    Correspondence
    Corresponding authors at: Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain.
    Affiliations
    Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain

    Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain

    Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain

    Medical Sciences Department, University of Girona, Girona, Spain
    Search for articles by this author
  • Jordi Gich
    Correspondence
    Corresponding authors at: Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain.
    Affiliations
    Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain

    Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain

    Medical Sciences Department, University of Girona, Girona, Spain
    Search for articles by this author
Published:November 04, 2022DOI:https://doi.org/10.1016/j.msard.2022.104397

      Abstract

      Background

      The presence of lipid-specific oligoclonal IgM bands (LS-OCMB) in cerebrospinal fluid is associated with a more severe clinical multiple sclerosis (MS) course.

      Objective

      To investigate LS-OCMB as a prognostic biomarker of cognitive long-term outcomes in MS.

      Methods

      Ninety-nine patients underwent neuropsychological assessment. Cognitive performance between LS-OCMB– and LS-OCMB+ patients was compared adjusting by age, education, anxiety-depression, disease duration, and disability.

      Results

      LS-OCMB+ patients of ∼13 years of disease duration performed worse on Symbol Digit Modalities Test (SDMT) (p = 0.005).

      Conclusion

      LS-OCMB+ perform worse on information processing speed and working memory (SDMT), suggesting that LS-OCMB could be a useful biomarker for long-term cognitive outcomes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ruano L.
        • Portaccio E.
        • Goretti B.
        • Niccolai C.
        • Severo M.
        • Patti F.
        • et al.
        Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
        Mult. Scler. J. 2017; 23 ([Internet]Aug 13Available from:): 1258-1267
        • Campbell J.
        • Rashid W.
        • Cercignani M.
        • Langdon D.
        Cognitive impairment among patients with multiple sclerosis: associations with employment and quality of life.
        Postgrad. Med. J. 2017; 93 ([Internet]MarAvailable from:): 143-147
        • Thangarajh M.
        • Gomez-Rial J.
        • Hedström A.K.
        • Hillert J.
        • Alvarez-Cermeño J.C.
        • Masterman T.
        • et al.
        Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis.
        Mult. Scler. 2008; 14 ([Internet][cited 2015 Jan 5]Available from:): 1208-1213
        • Rocca M.A.
        • Amato M.P.
        • De Stefano N.
        • Enzinger C.
        • Geurts J.J.
        • Penner I.K.
        • et al.
        Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis.
        Lancet Neurol. 2015; 14 ([Internet]Available from:): 302-317https://doi.org/10.1016/S1474-4422(14)70250-9
        • Sapko K.
        • Jamroz-Wišniewska A.
        • Marciniec M.
        • Kulczyñski M.
        • Szczepañska-Szerej A.
        • Rejdak K.
        Biomarkers in multiple sclerosis: a review of diagnostic and prognostic factors.
        Neurol. i Neurochir. Polska Via Med. 2020; 54: 42-48
        • Capuano R.
        • Zubizarreta I.
        • Alba-Arbalat S.
        • Sepulveda M.
        • Sola-Valls N.
        • Pulido-Valdeolivas I.
        • et al.
        Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability.
        Mult. Scler. J. 2021; 27: 1706-1716
        • Coll-Martinez C.
        • Quintana E.
        • Salavedra-Pont J.
        • Buxó M.
        • González-Del-Rio M.
        • Gómez I.
        • et al.
        Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis.
        Brain Behav. 2021; ([Internet]Nov 18Available from:): e2405
        • Zigmond A.S.
        • Snaith R.P.
        The hospital anxiety and depression scale.
        Acta Psychiatr. Scand. 1983; 67 (Jun): 361-370
        • Sepulcre J.
        • Vanotti S.
        • Hernández R.
        • Sandoval G.
        • Cáceres F.
        • Garcea O.
        • et al.
        Cognitive impairment in patients with multiple sclerosis using the brief repeatable battery-neuropsychology test.
        Mult. Scler. J. 2006; 12 ([Internet]Available from:): 187-195
        • Sumowski J.F.
        • Leavitt V.M.
        Cognitive reserve in multiple sclerosis.
        Mult. Scler. J. 2013; 19 ([Internet]Available from:): 1122-1127